基本信息
浏览量:90
职业迁徙
个人简介
Since his return to the CHU of Quebec, he has set up a new radiopeptide therapy program for neuroendocrine tumors. His research program is multidisciplinary and integrates translational research projects in medical and clinical physics.
Dr. Beauregard’s main clinical research project is the radiopeptide therapy (or PRRT for peptide receptor radionuclide therapy) of patients with neuroendocrine tumors (NETs), where a radioligand (ex. 177Lu-octreotate), binding to the somatostatin receptor expressed by NETs, is administered in several cycles to deliver radiotherapy said internal. We have developed an innovative approach, the personalization of the administered activity, to achieve safe target doses of radiation absorbed by healthy tissue, in order to maximize the irradiation of tumors, without increasing the treatment’s toxicity. Our preliminary results show that we are substantially increasing the radiation dose to tumors compared to the standard regimen where all patients receive the same activity at each cycle.
At the same time, we are working to improve and simplify dosimetry based on SPECT / CT quantitative imaging. To this end, we are fine-tuning the calibration of the SPECT / CT cameras and optimizing the sequence of serial imaging of patient performed after each PRRT treatment cycle in order to achieve the highest precision possible with a minimum of imaging sessions. These serial studies allow us to evaluate the biodistribution of the radiopharmaceutical and its kinetics in different tissues and tumors to derive absorbed radiation doses.
In collaboration with Dr. Girish M. Shah, we are also conducting in vitro and in vivo translational research projects, evaluating novel approaches to PRRT potentiation. One of these is the coadministration of radiosensitizing molecules, such as poly (ADP-ribose) and polymerase (PARP) inhibitors. These inhibit the repair of damages caused to the tumors’ DNA by the PRRT, and thus amplify the therapeutic effects. Another strategy we are studying is to pre-treat NET cells with molecules that can increase their somatostatin receptor expression, thereby promoting increased PRRT radiopharmaceutical accumulation within these cells.
Finally, Dr. Beauregard is also a co-investigator and collaborator on several other clinical research projects using, among other things, positron emission tomography (PET / CT) molecular imaging of prostate cancer and neurodegenerative disorders. Dr. Beauregard supervises graduate students and clinical fellows as part of a complementary training program in nuclear oncology.
Dr. Beauregard’s main clinical research project is the radiopeptide therapy (or PRRT for peptide receptor radionuclide therapy) of patients with neuroendocrine tumors (NETs), where a radioligand (ex. 177Lu-octreotate), binding to the somatostatin receptor expressed by NETs, is administered in several cycles to deliver radiotherapy said internal. We have developed an innovative approach, the personalization of the administered activity, to achieve safe target doses of radiation absorbed by healthy tissue, in order to maximize the irradiation of tumors, without increasing the treatment’s toxicity. Our preliminary results show that we are substantially increasing the radiation dose to tumors compared to the standard regimen where all patients receive the same activity at each cycle.
At the same time, we are working to improve and simplify dosimetry based on SPECT / CT quantitative imaging. To this end, we are fine-tuning the calibration of the SPECT / CT cameras and optimizing the sequence of serial imaging of patient performed after each PRRT treatment cycle in order to achieve the highest precision possible with a minimum of imaging sessions. These serial studies allow us to evaluate the biodistribution of the radiopharmaceutical and its kinetics in different tissues and tumors to derive absorbed radiation doses.
In collaboration with Dr. Girish M. Shah, we are also conducting in vitro and in vivo translational research projects, evaluating novel approaches to PRRT potentiation. One of these is the coadministration of radiosensitizing molecules, such as poly (ADP-ribose) and polymerase (PARP) inhibitors. These inhibit the repair of damages caused to the tumors’ DNA by the PRRT, and thus amplify the therapeutic effects. Another strategy we are studying is to pre-treat NET cells with molecules that can increase their somatostatin receptor expression, thereby promoting increased PRRT radiopharmaceutical accumulation within these cells.
Finally, Dr. Beauregard is also a co-investigator and collaborator on several other clinical research projects using, among other things, positron emission tomography (PET / CT) molecular imaging of prostate cancer and neurodegenerative disorders. Dr. Beauregard supervises graduate students and clinical fellows as part of a complementary training program in nuclear oncology.
研究兴趣
论文共 140 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Seval Beykan Schürrle,Uta Eberlein,Catherine Ansquer,Jean-Mathieu Beauregard, Lucie Durand-Gasselin,Henning Grønbæk,Alexander Haug,Rodney J Hicks,Nat P Lenzo,Shaunak Navalkissoor,Guillaume P Nicolas, Ben Pais,
European journal of nuclear medicine and molecular imaging (2024)
Zahra Mansouri,Yazdan Salimi,Azadeh Akhavanallaf,Isaac Shiri, Eliluane Pirazzo Andrade Teixeira,Xinchi Hou,Jean-Mathieu Beauregard,Arman Rahmim,Habib Zaidi
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2024)
Seval Beykan Schürrle,Uta Eberlein,Catherine Ansquer,Jean-Mathieu Beauregard, Lucie Durand-Gasselin,Henning Grønbæk,Alexander Haug,Rodney J. Hicks,Nat P. Lenzo,Shaunak Navalkissoor,Guillaume P. Nicolas, Ben Pais,
European Journal of Nuclear Medicine and Molecular Imagingpp.1-14, (2024)
Zahra Mansouri,Yazdan Salimi,Azadeh Akhavanallaf,Isaac Shiri, Eliluane Pirazzo Andrade Teixeira,Xinchi Hou,Jean-Mathieu Beauregard,Arman Rahmim,Habib Zaidi
European journal of nuclear medicine and molecular imagingpp.1-14, (2024)
Clinical nuclear medicineno. 1 (2023): E12-E15
引用0浏览0WOS引用
0
0
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): 5033-5033
引用0浏览0引用
0
0
The Lancet Oncologyno. 6 (2023): 597-610
JOURNAL OF NUCLEAR MEDICINE (2023)
引用0浏览0引用
0
0
JOURNAL OF NUCLEAR MEDICINE (2022)
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn